Biolife secures AU patent for cancer vaccine
Biolife Science has been granted an Australian patent covering cancer vaccine candidate HER-Vaxx.
The patent covers HER-Vaxx’s action against cancers associated with tumour antigen protein HER-2/neu. It grants Biolife Science intellectual property protection through to 2027.
HER-Vaxx is designed to stimulate HER-2 antibodies in early-stage cancer patients and has the potential to be a more potent alternative to Roche’s injectable antibody Herceptin. Nearly 20% of stomach cancers and 25-30% of breast cancers are HER-2 positive.
“With our intellectual property for HER-Vaxx now secured, we will have added confidence in its commercial viability moving forward,” Biolife Chariman-elect Dr Roger Aston said.
Biolife is currently conducting a backdoor ASX listing through a reverse takeover with ASX shell company Acuvax and an associated placement.
The company aims to raise up to $5 million through the placement to help fund phase II clinical trials for HER-Vaxx. Dr Aston and Paul Hooper have been selected to help lead the combined company.
“Biolife is eager to finalise its listing on the ASX and proceed with clinical trials of HER-Vaxx to further prove its effectiveness,” Dr Aston said.
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
Preventing neural graft rejection in Parkinson's patients
Researchers have engineered a way to fool the immune system into accepting neural grafts as part...
Retinal health linked to dementia risk, study shows
Researchers have discovered that the blood vessels at the back of the eye — called retinal...
